BioLife Solutions HR chief sells 219 shares

BioLife Solutions Inc. executive files small preplanned stock sale.

Rhea-AI Filing Summary

BioLife Solutions Inc. executive files small preplanned stock sale. Chief Human Resources Officer Sarah Aebersold sold 219 shares of common stock on March 3, 2026 in an open-market transaction at $20.74 per share. The sale was made under a Rule 10b5-1(c) trading plan adopted effective February 24, 2022 to satisfy tax withholding obligations from vested restricted stock. After this transaction, she directly holds 93,360 shares of BioLife Solutions common stock.

Insider Trade Summary

Net Seller: 219 shares

Net Sell 1 txn

Insider Aebersold Sarah

Role Chief Human Resources Officer

Sold 219 shs ($5K)

Type	Security	Shares	Price	Value
Sale	Common Stock	219	$20.74	$5K

Holdings After Transaction: Common Stock — 93,360 shares (Direct)

Footnotes (1)

1. F1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioLife Solutions (BLFS) report for Sarah Aebersold?

BioLife Solutions reported that Chief Human Resources Officer Sarah Aebersold sold 219 shares of common stock in an open-market transaction at $20.74 per share. This transaction was disclosed on a Form 4 insider filing for the company’s stock.

Was the BLFS insider sale by Sarah Aebersold part of a preplanned Rule 10b5-1 plan?

Yes. The Form 4 states the 219-share sale was executed under a Rule 10b5-1(c) trading plan adopted by Sarah Aebersold effective February 24, 2022, specifically to cover tax withholding obligations related to vesting of restricted stock awards.

How many BioLife Solutions (BLFS) shares does Sarah Aebersold hold after the reported sale?

Following the reported transaction, Sarah Aebersold directly owns 93,360 shares of BioLife Solutions common stock. This post-transaction ownership figure is disclosed in the Form 4 and reflects her remaining direct equity interest after selling 219 shares.

What was the price per share for the BioLife Solutions (BLFS) insider sale?

The open-market sale by Sarah Aebersold was executed at $20.74 per share for 219 shares of BioLife Solutions common stock. This per-share price is explicitly reported in the Form 4 insider trading disclosure.

What is the role of Sarah Aebersold at BioLife Solutions (BLFS) in this Form 4 filing?

In this Form 4, Sarah Aebersold is identified as an officer of BioLife Solutions, serving as Chief Human Resources Officer. She is not reported as a director or ten percent owner in the insider ownership details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 05:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aebersold Sarah

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		219	D	$20.74	93,360	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Sarah Aebersold	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.